The primary goal of the Atlantic Anti-Platelet Initiative (AAPI) was to develop evidence- based guidelines for the acute administration of oral anti-platelet therapy in patients presenting with ACS in Atlantic Canada. Although dual anti-platelet therapy with aspirin and clopidogrel is well established as the regional standard of care, there is currently significant uncertainty in Atlantic Canada about how the novel P2Yi inhibitors prasugrel and ticagrelor should be incorporated into clinical practice. Furthermore, although Canadian Cardiovascular Society anti-platelet guidelines were recently published, they focus on anti-platelet therapy in the outpatient setting and do not address the acute phase of ACS care.
Video Footage of Panelists providing insight on the AAPI Recommendation rationale & process
Atlantic Anti Platelet Initiative (AAPI) Panelists have created video taped answers to questions which address both the rationale and clinical insight that influenced their debate & decision making. Please take a few minutes to review questions & answers that are of interest to you from Panelists who represented your geographic region.
Thereafter, feel free to review Panelist’s videos from throughout Atlantic Canada. If you are in search of an answer which is not provided, please contact Pat Lively (Pat.Lively@HorizonNB.ca) and a Panelist will promptly provide an answer. Any and all feedback regarding the value this tool offers you would be sincerely appreciated!
The Atlantic Cardiovascular Society is a new organization with unique intentions. Formed by a core group of cardiovascular practitioners throughout the Atlantic Provinces; its focus will be health issues unique to Atlantic Canada. Read more